Clinical trial
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When…
NCT00323050 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00323050 |
|---|---|
| Title | Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects |
| Official title | Evaluate Immunogenicity,Safety & Reactogenicity of a Booster Dose of Hib-MenC Conjugate Vaccine When Given to Healthy Subjects Aged 13-14 Months Who Were Primed With 3 Doses of Hib-MenC vs a Booster Dose of Infanrix Hexa Given to Subjects Primed With 3 Doses of Infanrix Hexa and Meningitec |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neisseria Meningitidis, Haemophilus Influenzae Type b |
| Intervention type | Biological |
| Interventions | Haemophilus influenzae type b- and meningococcal (vaccine) |
| Enrollment | 468 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | May 9, 2006 |
| Last update posted | Sep 16, 2016 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: